- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00217815
Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer
A Phase Ib, Pharmacokinetic, Multiple Center, Open Label Study Evaluating the Safety and Efficacy of Mycograb Administered IV in Combination With Docetaxel in Metastatic or Recurrent Breast Cancer Patients
Study Overview
Detailed Description
Combination therapies that incorporate new agents have demonstrated the potential to improve outcome for patients with metastatic breast carcinoma. Docetaxel has been shown to be a very active drug in breast cancer, and anthracycline-based chemotherapy combinations represent the most active form of therapy generating objective response rates of between 40-70%. Mycograb® was most effective in breast carcinoma cell lines in combination with cisplatin, docetaxel and anthracyclines (doxorubicin, daunorubicin).
We propose that Mycograb® binds to hsp90, inhibiting hsp90 chaperone functioning and resulting in the destabilization of key proteins including estrogen/steroid receptors, nitric oxide synthase, ras1, MAP (Mitogen-activated protein) kinase, Src, Erb-B2,(erythroblastic leukemia viral oncogene homolog 2) HER(human estrogen receptor) kinases and EGFR (epidermal grown factor receptor). Over expression of HER2 receptors are observed in malignancies such as breast cancer and reportedly have been associated with resistance to chemotherapeutic agents. Both maturing and fully mature forms of the receptor depend on hsp90 association for stability. Inhibition of hsp90 function down regulates AKT kinase and Src kinase which are non-receptor kinase. Therefore, Mycograb® may be of use in estrogen dependent and hormone independent breast cancers.
Mycograb® has been demonstrated to have anti-tumor activity in cell culture. The 50% cytotoxicity of Mycograb® on its own is 50 Combination therapies that incorporate new agents have demonstrated the potential to improve outcome for patients with metastatic breast carcinoma. Docetaxel has been shown to be a very active drug in breast cancer, and anthracycline-based chemotherapy combinations represent the most active form of therapy generating objective response rates of between 40-70%. Mycograb® was most effective in breast carcinoma cell lines in combination with cisplatin, docetaxel and anthracyclines (doxorubicin, daunorubicin).
We propose that Mycograb® binds to hsp90, inhibiting hsp90 chaperone functioning and resulting in the destabilization of key proteins including estrogen/steroid receptors, nitric oxide synthase, ras1, MAP kinase, Src, Erb-B2, HER kinases and EGFR. Overexpression of HER2 receptors are observed in malignancies such as breast cancer and reportedly have been associated with resistance to chemotherapeutic agents. Both maturing and fully mature forms of the receptor depend on hsp90 association for stability. Inhibition of hsp90 function down regulates AKT kinase and Src kinase which are non-receptor kinase. Therefore, Mycograb® may be of use in estrogen dependent and hormone independent breast cancers.
Mycograb® has been demonstrated to have anti-tumor activity in cell culture. The 50% cytotoxicity of Mycograb® on its own is 50 µg/ml (MCF7 [Breast cancer cell line designation]). Mycograb® in combination with docetaxel, doxorubicin and cisplatin and Herceptin increased the cytotoxicity in breast cancer cells.
It is appropriate to evaluate the apparent tumor response and survivor benefits resulting from the addition of Mycograb® to a docetaxel containing chemotherapy regimen in metastatic or recurrent breast cancer patients.
(MCF7). Mycograb® in combination with docetaxel, doxorubicin and cisplatin and Herceptin increased the cytotoxicity in breast cancer cells.
It is appropriate to evaluate the apparent tumor response and survivor benefits resulting from the addition of Mycograb® to a docetaxel containing chemotherapy regimen in metastatic or recurrent breast cancer patients.
Study Type
Enrollment
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Pabianicka
-
Lodz, Pabianicka, Poland, 93-513
- Chemotherapie Clinic of Medical University Lodz
-
-
-
-
Belgrade
-
Bezanijska Kosa bb, Belgrade, Serbia, 11000
- Clinical Hospital Centre Bezanijska Kosa
-
Pasterova 14, Belgrade, Serbia, 11000
- Institute for Oncology and Radiology of Serbia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must be female between the ages of 18 to 70 years old.
- Patients must have histologically or clinically confirmed metastatic and/or recurrent breast cancer amenable to treatment with docetaxel.
- Patients must have presence of at least one uni-dimensional measurable lesion with minimal lesion size > 20 mm at the largest diameter.
- Patients may have had one previous chemotherapy regimen and must not have received prior chemotherapy with docetaxel.
- Patients must have been off all hormonal therapy for at least 2 weeks prior to initiation of therapy.
- Patients must have been off all chemotherapy or radiotherapy regimens for at least 4 weeks prior to initiation of chemotherapy.
- Patients must have a life expectancy of at least 6 months.
- Patients must have a ECOG status of 0, 1 or 2.
- Patients must be willing to complete all procedures and visits as outlined in the protocol.
- Patients must sign an informed consent form.
- Patients must have negative blood test for HIV and hepatitis B and C.
- Female patients of child bearing potential should use an effective method of contraception.
Exclusion Criteria:
- Patients with brain or meningeal metastases.
- Patients whose only measurable lesion is in the bone.
- Patients with clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, respiratory, neurologic, psychiatric, immunologic, gastrointestinal, hematologic, metabolic or any other condition or laboratory abnormality that in the opinion of the investigator makes the patient unsuitable for participation in the study.
- Patients with history of seizure disorder.
- Patients who have received treatment with any other investigational drug within the preceding one month.
- Patients who are pregnant or breast feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Impact on tumour size when compared to historical controls
|
Secondary Outcome Measures
Outcome Measure |
---|
Safety data
|
Pharmacokinetics data
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anna Pluzanska, MD, University of Lodz
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NTP/ONC/001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer of the Breast
-
Washington University School of MedicineNational Institute for Biomedical Imaging and Bioengineering (NIBIB)CompletedBreast Cancer | Breast Tumors | Cancer of Breast | Malignant Neoplasm of Breast | Cancer of the BreastUnited States
-
Washington University School of MedicineTerminatedBreast Cancer | Cancer of Breast | Cancer of the BreastUnited States
-
Nuvation Bio Inc.WithdrawnBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Breast Carcinoma | Cancer of Breast | Malignant Tumor of Breast | Breast Tumor | Cancer of the BreastUnited States
-
Synermore Biologics Co., Ltd.CompletedColon Cancer, Breast Cancer, Cancer of the Head and NeckUnited States
-
Zhejiang Cancer HospitalUnknownEvaluation of the Value of Mammaprint Test Gene Variation in the Prediction of Neoadjuvant Chemotherapy for Breast CancerChina
-
Washington University School of MedicineCompletedBreast Cancer | Breast Neoplasms | Cancer of Breast | Cancer of the BreastUnited States
-
Emory UniversityCompletedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of Breast | Cancer of the Breast | Human Mammary CarcinomaUnited States
-
Samuel AchilefuRecruitingBreast Cancer | Cancer of the BreastUnited States
-
Washington University School of MedicineRecruitingBreast Cancer | Cancer of the BreastUnited States
-
Washington University School of MedicineBiovicaRecruiting
Clinical Trials on Mycograb, Docetaxel
-
Novartis PharmaceuticalsTerminatedCryptococcal MeningitisUnited States
-
Nereus Pharmaceuticals, Inc.CompletedCancerUnited States, Australia, India, Chile, Brazil, Argentina
-
Tianjin Medical University Cancer Institute and...Recruiting
-
Zhuhai Beihai Biotech Co., LtdCompletedSolid Tumours | Bioequivalence | DocetaxelIndia
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaCompletedNon-Small Cell Lung Cancer (NSCLC)China
-
National Cancer Center, KoreaSeoul National University Bundang Hospital; Gachon University Gil Medical Center and other collaboratorsUnknownGastric CancerKorea, Republic of
-
Optimal Health ResearchCompletedBreast Cancer | Lung Cancer | Prostate CancerUnited States
-
Arog Pharmaceuticals, Inc.WithdrawnCarcinoma, Non-Small-Cell Lung
-
Boehringer IngelheimCompletedCarcinoma, Non-Small-Cell LungJapan
-
SanofiCompleted